TY - JOUR
T1 - Hepatitis B vaccination uptake and correlates of serologic response among HIV-infected and uninfected men who have sex with men (MSM) in Bangkok, Thailand
AU - Chonwattana, Wannee
AU - Raengsakulrach, Boonyos
AU - Holtz, Timothy H.
AU - Wasinrapee, Punneeporn
AU - Tongtoyai, Jaray
AU - Chaikummao, Supaporn
AU - Pattanasin, Sarika
AU - McNicholl, Janet M.
AU - van Griensven, Frits
AU - Curlin, Marcel
PY - 2015/5/15
Y1 - 2015/5/15
N2 - Background: Vaccination against hepatitis B virus (HBV) is recommended for all HBV-susceptible men who have sex with men (MSM). There is limited information on correlates of immunity to HBV vaccination in this group. We present serologic response rates to hepatitis B vaccine and identify factors associated with impaired response among HIV-uninfected and HIV-infected Thai MSM. Methodology: HBV-susceptible volunteers were offered hepatitis B vaccination at months zero, one, and six. We measured baseline (pre-vaccination) total serum IgG and IgG subclasses (all participants), baseline CD4 count, and plasma HIV-1 viral load (PVL) (HIV+ participants). HBV serologies were retested at 12 months. Serologic responses were compared between all groups in men receiving three vaccine doses. Results: 511/651 HIV-negative and 64/84 HIV-positive participants completed the three-dose series. Response rates in HIV-uninfected and -infected participants were 90.1% vs. 50.0% (p 1550. mg/dL and PVL >10,000 copies/mL were almost always non-responsive (p
AB - Background: Vaccination against hepatitis B virus (HBV) is recommended for all HBV-susceptible men who have sex with men (MSM). There is limited information on correlates of immunity to HBV vaccination in this group. We present serologic response rates to hepatitis B vaccine and identify factors associated with impaired response among HIV-uninfected and HIV-infected Thai MSM. Methodology: HBV-susceptible volunteers were offered hepatitis B vaccination at months zero, one, and six. We measured baseline (pre-vaccination) total serum IgG and IgG subclasses (all participants), baseline CD4 count, and plasma HIV-1 viral load (PVL) (HIV+ participants). HBV serologies were retested at 12 months. Serologic responses were compared between all groups in men receiving three vaccine doses. Results: 511/651 HIV-negative and 64/84 HIV-positive participants completed the three-dose series. Response rates in HIV-uninfected and -infected participants were 90.1% vs. 50.0% (p 1550. mg/dL and PVL >10,000 copies/mL were almost always non-responsive (p
KW - HBV
KW - HIV
KW - IgG
KW - Plasma viral load
KW - Serologic response
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=84960354717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960354717&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2015.11.071
DO - 10.1016/j.vaccine.2015.11.071
M3 - Article
C2 - 26685092
AN - SCOPUS:84960354717
JO - Vaccine
JF - Vaccine
SN - 0264-410X
ER -